Patents by Inventor Wai Kit LAW

Wai Kit LAW has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
    Patent number: 9968616
    Abstract: Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 15, 2018
    Assignee: THE CHINESE UNIVERSITY OF HONG KONG
    Inventors: David Chi Cheong Wan, Yan Wang, Wai Kit Law, Jian Shu Hu, Tsz Ming Ip
  • DISCOVERY OF FDA-APPROVED DRUGS AS INHIBITORS OF FATTY ACID BINDING PROTEIN 4 USING MOLECULAR DOCKING SCREENING
    Publication number: 20160113937
    Abstract: Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (FABP4). The present invention provides a novel use of levofloxacin as an inhibitor of FABP4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases. The present invention further provides a method of using levofloxacin to inhibit FABP4, or to inhibit adipolysis in adipocytes.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 28, 2016
    Inventors: David Chi Cheong WAN, Yan WANG, Wai Kit LAW, Jian Shu HU, Tsz Ming IP